Marinus Pharmaceuticals I... (MRNS)
NASDAQ: MRNS
· Real-Time Price · USD
0.55
0.00 (0.00%)
At close: Feb 10, 2025, 3:59 PM
Marinus Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 31.47M | 30.26M | 28.29M | 30.99M | 30.96M | 25.96M | 21.67M | 25.48M | 19.84M | 27.61M | 27.73M | 15.35M | 15.37M | 5.43M | 3.52M |
Cost of Revenue | 3.49M | 3.23M | 2.74M | 2.06M | 1.34M | 932K | 22.04M | 23M | 40.73M | 42.16M | 39.22M | 56.65M | 51.08M | 60.9M | 54.09M |
Gross Profit | 27.98M | 27.03M | 25.55M | 28.93M | 29.62M | 25.03M | -369K | 2.47M | -20.89M | -14.55M | -11.5M | -41.3M | -35.7M | -55.48M | -50.57M |
Operating Income | -124.57M | -135.14M | -134.34M | -131.49M | -125.26M | -123.71M | -129.04M | -113.96M | -111.86M | -100.93M | -87.65M | -96.93M | -87.32M | -83.85M | -76.25M |
Interest Income | 4.92M | 6.21M | 7.23M | 8.11M | 8.11M | 6.73M | 4.68M | 2.35M | 633K | 136K | 68K | 80K | 97K | 159K | 355K |
Pretax Income | -140.49M | -149.24M | -146.88M | -142.94M | -133.85M | -25.84M | -31.8M | -16.43M | -12.06M | -106.61M | -91M | -98.78M | -87.94M | -84.09M | -75.94M |
Net Income | -140.49M | -149.24M | -145.34M | -141.25M | -133.79M | -29.18M | -36.68M | -23.16M | -17.16M | -108.3M | -92.69M | -98.78M | -87.94M | -84.09M | -75.94M |
Selling & General & Admin | 63.27M | 65.56M | 64.57M | 61.15M | 60.45M | 58.97M | 60.31M | 56.84M | 52.81M | 48.87M | 38.64M | 37.28M | 32.66M | 27.77M | 25.07M |
Research & Development | 87.47M | 94.8M | 95.32M | 99.26M | 94.43M | 89.77M | 89.85M | 79.91M | 76.5M | 75.85M | 72.92M | 73.52M | 68.55M | 61.5M | 54.69M |
Other Expenses | 36K | 36K | 83K | 84K | 84K | 84K | -58K | 1.07M | 1.42M | 1.42M | 1.51M | 334K | -27K | -66K | -68K |
Operating Expenses | 150.74M | 160.36M | 159.89M | 160.41M | 154.88M | 148.74M | 150.17M | 137.93M | 130.48M | 125.89M | 112.73M | 110.8M | 101.21M | 89.28M | 79.77M |
Interest Expense | 17.1M | 17.5M | 17.09M | 16.89M | 16.29M | 14.68M | 13.13M | 10.67M | 8.54M | 6.58M | 4.27M | 2.58M | 1.03M | 351K | n/a |
Selling & Marketing Expenses | 2.78M | 2.78M | -364K | -364K | -28.7M | -28.7M | -28.7M | -28.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 154.09M | 163.45M | 162.63M | 162.47M | 156.22M | 149.68M | 150.71M | 138.27M | 130.53M | 127.37M | 114.21M | 112.28M | 102.69M | 89.28M | 79.77M |
Income Tax Expense | 87.72K | -54.28K | -1.59M | -1.84M | -200K | 1.69M | 3.23M | 5.08M | 3.44M | 1.69M | 1.69M | -24K | -172K | -251K | -251K |
Shares Outstanding (Basic) | 57.23M | 57.06M | 56.85M | 56.69M | 53.92M | 52.55M | 51.77M | 44.97M | 37.2M | 37.16M | 36.89M | 36.73M | 36.74M | 36.65M | 36.6M |
Shares Outstanding (Diluted) | 57.23M | 57.06M | 56.85M | 56.69M | 53.92M | 52.55M | 51.77M | 44.97M | 37.91M | 37.16M | 36.89M | 36.75M | 36.74M | 36.66M | 36.6M |
EPS (Basic) | -2.47 | -2.66 | -2.64 | -2.63 | -2.65 | -0.11 | -0.56 | -0.46 | -0.47 | -2.93 | -2.52 | -2.69 | -2.47 | -2.45 | -2.43 |
EPS (Diluted) | -2.47 | -2.66 | -2.64 | -2.63 | -2.65 | -0.15 | -0.6 | -0.5 | -0.51 | -2.93 | -2.52 | -2.69 | -2.47 | -2.45 | -2.43 |
EBITDA | -123.69M | -131.15M | -129.17M | -125.35M | -116.85M | -118.25M | -125.84M | -112.97M | -110.71M | -99.42M | -86.13M | -95.68M | -86.51M | -83.48M | -75.62M |
EBIT | -123.39M | -131.74M | -129.79M | -126.05M | -117.56M | -11.16M | -18.67M | -5.75M | -3.52M | -100.03M | -86.72M | -96.19M | -86.94M | -83.78M | -75.98M |
Depreciation & Amortization | 530K | 582K | 618K | 697K | 711K | 683K | 685K | 640K | 674K | 687K | 674K | 667K | 588K | 491K | 411K |